Financial Performance Highlights

Quarter Ended September 30, 2026 (Q2 FY27):

  • Revenue from Operations: ₹4,837.89 lakh (compared to ₹5,100.22 lakh in Q2 FY26)
  • Other Income: ₹1.98 lakh (compared to ₹28.93 lakh in Q2 FY26)
  • Total Income: ₹4,839.87 lakh (compared to ₹5,129.15 lakh in Q2 FY26)
  • Profit Before Tax: ₹122.10 lakh (compared to ₹267.37 lakh in Q2 FY26)
  • Net Profit: ₹79.94 lakh (compared to ₹115.60 lakh in Q2 FY26)
  • Basic EPS: ₹0.80 (compared to ₹1.19 in Q2 FY26)

Half Year Ended September 30, 2026 (H1 FY27):

  • Revenue from Operations: ₹9,680.95 lakh (compared to ₹10,481.54 lakh in H1 FY26)
  • Other Income: ₹43.87 lakh (compared to ₹83.89 lakh in H1 FY26)
  • Total Income: ₹9,724.82 lakh (compared to ₹10,565.43 lakh in H1 FY26)
  • Profit Before Tax: ₹274.94 lakh (compared to ₹483.80 lakh in H1 FY26)
  • Net Profit: ₹191.28 lakh (compared to ₹256.10 lakh in H1 FY26)
  • Basic EPS: ₹1.92 (compared to ₹2.64 in H1 FY26)

Operational Details

  • Q2 FY27 sales turnover of ₹4,837.89 lakh comprised Domestic Turnover of ₹4,379.52 lakh and Export Turnover of ₹458.37 lakh
  • The company operates in one reportable business segment: Active Pharmaceutical Ingredients (API) and their Intermediates
  • 2,63,157 Equity Share Warrants were issued earlier @ ₹152 per Warrant
  • During the quarter, the company received the remaining 75% payment for warrants received earlier, and 1,76,870 equity shares were considered for EPS calculation

Capital Structure Changes

  • Paid-up equity share capital increased to ₹997.37 lakh as of September 30, 2026 (from ₹971.05 lakh as of March 31, 2026)
  • Reserves excluding Revaluation Reserves stood at ₹7,041.73 lakh as of September 30, 2026 (from ₹6,576.77 lakh as of March 31, 2026)
  • The increase represents issuance of 26,232 equity shares during the period

Balance Sheet Position (as of September 30, 2026)

Assets: ₹23,837.32 lakh

  • Non-current Assets: ₹7,080.61 lakh (Property, Plant & Equipment: ₹4,115.17 lakh; Capital Work-in-Progress: ₹2,103.69 lakh)
  • Current Assets: ₹16,756.70 lakh (Inventories: ₹4,180.11 lakh; Trade Receivables: ₹12,016.90 lakh; Cash & Cash Equivalents: ₹29.74 lakh)

Liabilities & Equity: ₹23,837.32 lakh

  • Equity: ₹8,039.10 lakh
  • Non-current Liabilities: ₹1,455.69 lakh (Borrowings: ₹965.58 lakh)
  • Current Liabilities: ₹14,342.52 lakh (Borrowings: ₹3,954.31 lakh; Trade Payables: ₹5,671.54 lakh)

Cash Flow Statement (H1 FY27)

  • Net Cash from Operating Activities: (₹98.35) lakh
  • Net Cash from Investing Activities: (₹91.81) lakh
  • Net Cash from Financing Activities: ₹209.73 lakh
  • Net Increase in Cash: ₹19.57 lakh
  • Cash flow includes securities premium received of ₹273.68 lakh on issue of equity shares

Auditor's Limited Review Report

M/s. P.S.N Ravishanker & Associates issued a qualified limited review report noting:

  • The Telangana State Pollution Control Board (TSPCB) revocation order dated February 4, 2022, stipulates the company cannot exceed production capacity indicated in its November 22, 2017 order
  • The company is operating at substantially enhanced production levels without necessary TSPCB approvals (Consent for Establishment and Consent for Operation)
  • This non-compliance could impact the going concern status through potential closure orders
  • Management stated they have applied for Consent for Establishment for enhanced capacities, pending approval, while having obtained Environmental Clearance Certificate

The financial results were prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 and Regulation 33 of SEBI Listing Regulations.